8-K: Henry Schein Announces Strategic Investment by KKR, Board Changes, and Preliminary 2025 Financial Guidance

Henry Schein secures a strategic $250 million investment from KKR, welcomes new board members, and projects low to mid-single digit growth in 2025 non-GAAP EPS.

Summary

• Henry Schein has entered into a strategic partnership with KKR, involving a $250 million investment in the company's common stock.
• KKR will become a 12% common shareholder and will have the option to increase its stake to 14.9% through open market purchases.
• Max Lin and William K. Dan Daniel from KKR will join Henry Schein's Board of Directors as independent directors.
• Robert J. Hombach has also been appointed as an independent director.
• Preliminary unaudited fourth-quarter 2024 GAAP diluted EPS is reported at $0.74, and non-GAAP diluted EPS at $1.19.
• The company's preliminary full-year 2024 revenue reached $12.7 billion.
• Preliminary full-year 2024 GAAP net income was $390 million, or $3.05 per diluted share, while non-GAAP net income was $605 million, or $4.74 per diluted share.
• Adjusted EBITDA for the fourth quarter was $270 million, with a full-year 2024 Adjusted EBITDA of $1,061 million.
• Operating cash flow for the fourth quarter and full year 2024 was $204 million and $848 million, respectively.
• Henry Schein projects low to mid-single digit growth in revenues and non-GAAP diluted earnings per share for 2025.
• Adjusted EBITDA is expected to grow in the mid-single digit range in 2025.
• The company's share repurchase program authorization has been increased by $500 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with a strategic investment, board enhancements, and projected growth. While there are some risks and a slight decrease in GAAP net income, the overall tone is optimistic.

Positives

• KKR's strategic investment validates Henry Schein's business model and growth potential.
• The addition of experienced executives to the Board enhances the company's expertise in finance, operations, and healthcare.
• The increased share repurchase program signals management's confidence in the company's future performance.
• The company is projecting growth in revenues, non-GAAP diluted EPS, and Adjusted EBITDA for 2025.

Negatives

• Preliminary full-year 2024 GAAP net income decreased by 6.3% compared to 2023.
• Preliminary full-year 2024 GAAP diluted EPS decreased by 3.5% compared to 2023.

Risks

• The possibility that the expected changes to the Board or the Investment are not consummated and that any of the anticipated benefits will not be realized or will not be realized within the expected time period.
• Dependence on third parties for the manufacture and supply of products.
• Ability to develop or acquire and maintain and protect new products and technologies that achieve market acceptance with acceptable margins.
• Transitional challenges associated with acquisitions, dispositions and joint ventures.
• Adverse changes in supplier rebates or other purchasing incentives.
• Security risks associated with information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident).
• Effects of a highly competitive and consolidating market.
• Changes in the health care industry.
• Risks from expansion of customer purchasing power and multi-tiered costing structures.
• Increases in shipping costs for products or other service issues with third-party shippers.
• General global and domestic macro-economic and political conditions, including inflation, deflation, recession, ongoing wars, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies, and changes to other economic indicators, international trade agreements, potential trade barriers and terrorism.
• Geopolitical wars.
• Failure to comply with existing and future regulatory requirements.
• Risks associated with the EU Medical Device Regulation.
• Failure to comply with laws and regulations relating to health care fraud or other laws and regulations.
• Failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions.
• Changes in tax legislation.
• Risks related to product liability, intellectual property and other claims.
• Risks associated with customs policies or legislative import restrictions.
• Risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters.
• Risks associated with global operations.
• Litigation risks.
• New or unanticipated litigation developments and the status of litigation matters.
• Dependence on senior management, employee hiring and retention, and relationships with customers, suppliers and manufacturers.
• Disruptions in financial markets.

Future Outlook

Henry Schein anticipates low to mid-single digit growth in revenues and non-GAAP diluted earnings per share for 2025, with Adjusted EBITDA expected to grow in the mid-single digit range.

Management Comments

• Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, stated that the Board and management have great respect for KKR and look forward to collaborating with the new directors.
• Max Lin stated that KKR is excited to support Henry Schein and believes the Company has tremendous growth potential.
• Robert J. Hombach stated that he is honored to join the Henry Schein Board and looks forward to contributing to creating significant value for all of Henry Schein's stakeholders.

Industry Context

The investment by KKR reflects a broader trend of private equity firms investing in the healthcare industry, seeking to leverage their operational expertise and capital to drive growth and improve efficiency. This partnership could enhance Henry Schein's competitive position in the healthcare solutions market.

Comparison to Industry Standards

• Comparing Henry Schein's projected growth rates to those of its competitors, such as Patterson Companies and McKesson, will provide a benchmark for assessing the company's performance.
• KKR's involvement could lead to operational improvements and strategic initiatives that align Henry Schein with industry best practices.
• The addition of experienced executives from companies like Danaher and Baxalta suggests a focus on operational excellence and financial discipline, which are key drivers of success in the healthcare industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through strategic initiatives and operational improvements.
• Employees: Potential for increased employee engagement through broad-based equity ownership.
• Customers: Continued focus on providing solutions to improve operational success and clinical outcomes.
• Suppliers: Collaboration with KKR may lead to new partnerships and opportunities.

Next Steps

• Consummation of the transactions is subject to customary closing conditions, including regulatory approvals.
• The company intends to release its fourth quarter and full-year 2024 financial results on February 25, 2025.
• Henry Schein and KKR will collaborate to pursue additional opportunities to create shareholder value.

Key Dates